Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial

Jong Chul Park (), Brendan Curti, Marcus Butler, Eric Wehrenberg-Klee, Joseph Elassal, Robert Tighe, Sailaja Battula, Gail Iodice, Howard L. Kaufman and John M. Kirkwood
Additional contact information
Jong Chul Park: Massachusetts General Hospital
Brendan Curti: Providence Portland Medical Center
Marcus Butler: Princess Margaret Cancer Center
Eric Wehrenberg-Klee: Massachusetts General Hospital
Joseph Elassal: Ankyra Therapeutics, Inc.
Robert Tighe: Ankyra Therapeutics, Inc.
Sailaja Battula: Ankyra Therapeutics, Inc.
Gail Iodice: Ankyra Therapeutics, Inc.
Howard L. Kaufman: Ankyra Therapeutics, Inc.
John M. Kirkwood: University of Pittsburgh

Nature Communications, 2025, vol. 16, issue 1, 1-12

Abstract: Abstract Anchored immunotherapy is a novel approach for retaining drugs within the tumour microenvironment. Tolododekin alfa is a first-in-class anchored Interleukin 12 (IL-12) linked to aluminum hydroxide. Safety and biological activity were evaluated in a Phase 1 clinical trial in patients with accessible advanced solid tumours in Part 1 of a 3-part trial. The primary objectives are safety and tolerability as well as determination of the recommended dose for expansion (RDE). Secondary objectives include pharmacokinetics (PK), pharmacodynamics, preliminary antitumour activity, and immunogenicity. Exploratory analyses include serum and tissue biomarkers. Fifteen patients were enrolled at escalating doses of tolododekin alfa given by injection every 3 weeks. There were no dose-limiting toxicities or treatment-related serious adverse events. PK/Pharmacodynamic measurements demonstrate retention of drug in the tumour. Biological activity demonstrates increased CD8+ T cells, Programmed Cell Death Ligand 1 (PD-L1) expression, and prolonged pro-inflammatory gene expression. Nine patients (60%) achieved stable disease with one partial response. At a median follow-up of 5.2 months, the median duration of stable disease was 5.3 months (range 3.6-7.6 months). Median progression-free survival (PFS) was not estimable (NE) (95% CI, 2.57 months – NE). These findings support continued clinical development of tolododekin alfa. ClinicalTrials.gov registration: NCT06171750.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-63579-9 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-63579-9

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-63579-9

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().